Skip to main content

Table 2 Clinical parameters, metabolic factors and adipose tissue compartment changes from baseline after 26 weeks of treatment in the intention-to-treat analysis

From: A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients

Characteristic Mean ± SD change from baseline to 26 weeks Mean [95% CI] changes from baseline (liraglutide vs placebo) P value
Liraglutide (n = 22) Placebo (n = 25)
Clinical parameters
 Body weight (kg) − 3.9 ± 3.6 − 0.6 ± 2.2 − 3.5 [− 5.3, − 1.8] < 0.001
 BMI (kg/m2) − 1.5 ± 1.4 − 0.2 ± 0.8 − 1.4 [− 2.0, − 0.7] < 0.001
 Waist circumference (cm) − 5 ± 4 0 ± 4 − 5 [− 8, − 2] < 0.001
 Hip circumference (cm) − 4 ± 5 − 2 ± 3 − 2 [− 5, 0] 0.067
 Waist-hip ratio − 0.01 ± 0.04 0.02 ± 0.05 − 0.01 [− 0.04, 0.01] 0.312
 Lean body mass (kg) − 2.3 ± 2.3 0.4 ± 2.9 − 2.7 [− 4.3, − 1.1] 0.001
 Lean body mass (%) 0.2 ± 1.7 0.8 ± 2.7 − 0.6 [− 1.9, 0.8] 0.403
Metabolic factors
 HbA1c (mmol/mol) − 8.5 ± 11.2 − 6.8 ± 9.3 − 4.0 [− 9.7, 1.6] 0.156
 HbA1c (%) − 0.8 ± 1.0 − 0.6 ± 0.8 − 0.4 [− 0.9, 0.1] 0.156
 Total cholesterol (mmol/L) 0.24 ± 1.09 − 0.42 ± 0.82 0.52 [− 0.05, 1.09] 0.073
 HDL-cholesterol (mmol/L) − 0.04 ± 0.12 − 0.05 ± 0.12 0.02 [− 0.05, 0.09] 0.657
 LDL-cholesterol (mmol/L) 0.15 ± 0.74 − 0.14 ± 0.74 0.22 [− 0.20, 0.63] 0.296
 Triglycerides (mmol/L) 0.28 ± 1.25 − 0.38 ± 1.30 0.40 [− 0.24, 1.04] 0.214
Adipose tissue compartments
 Subcutaneous AT (cm2) − 24 ± 37 − 10 ± 37 − 15 [− 37, 6] 0.158
 Visceral AT (cm2) − 20 ± 29 − 2 ± 17 − 13 [− 27, 1] 0.074
 Epicardial AT (cm2) 0 ± 2 1 ± 1 − 1 [− 2, 0] 0.232
 Paracardial AT (cm2) − 1 ± 3 0 ± 3 − 1 [− 2, 1] 0.494
 Hepatic TGC (%) − 1.2 ± 4.1 − 3.3 ± 5.4 0.4 [− 1.9, 2.8] 0.704
 Myocardial TGC (%) 0.1 ± 0.5 − 0.1 ± 0.6 0.2 [− 0.1, 0.5] 0.157
  1. Results are presented as n (%) or mean ± SD. n = 47. Missing data in the liraglutide group: n = 3 for epicardial adipose tissue volume and paracardial adipose tissue volume, n = 1 for myocardial TGC. Missing data in placebo group: n = 1 for lean body mass (kg and %), n = 3 for epicardial adipose tissue volume, n = 2 for paracardial adipose tissue volume, and n = 1 for myocardial TGC
  2. AT adipose tissue, TGC triglyceride content